JP2012525399A - トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 - Google Patents

トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 Download PDF

Info

Publication number
JP2012525399A
JP2012525399A JP2012508609A JP2012508609A JP2012525399A JP 2012525399 A JP2012525399 A JP 2012525399A JP 2012508609 A JP2012508609 A JP 2012508609A JP 2012508609 A JP2012508609 A JP 2012508609A JP 2012525399 A JP2012525399 A JP 2012525399A
Authority
JP
Japan
Prior art keywords
tocotrienol quinone
tocotrienol
alpha
individual
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012508609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525399A5 (cg-RX-API-DMAC7.html
Inventor
ガイ エム． ミラー，
Original Assignee
エジソン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エジソン ファーマシューティカルズ， インコーポレイテッド filed Critical エジソン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2012525399A publication Critical patent/JP2012525399A/ja
Publication of JP2012525399A5 publication Critical patent/JP2012525399A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012508609A 2009-04-28 2010-04-27 トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 Withdrawn JP2012525399A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21479509P 2009-04-28 2009-04-28
US61/214,795 2009-04-28
US31873310P 2010-03-29 2010-03-29
US61/318,733 2010-03-29
PCT/US2010/032624 WO2010126911A1 (en) 2009-04-28 2010-04-27 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014226669A Division JP2015028084A (ja) 2009-04-28 2014-11-07 トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療

Publications (2)

Publication Number Publication Date
JP2012525399A true JP2012525399A (ja) 2012-10-22
JP2012525399A5 JP2012525399A5 (cg-RX-API-DMAC7.html) 2013-07-11

Family

ID=42244195

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012508609A Withdrawn JP2012525399A (ja) 2009-04-28 2010-04-27 トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
JP2014226669A Withdrawn JP2015028084A (ja) 2009-04-28 2014-11-07 トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
JP2016183749A Pending JP2016216506A (ja) 2009-04-28 2016-09-21 トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014226669A Withdrawn JP2015028084A (ja) 2009-04-28 2014-11-07 トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
JP2016183749A Pending JP2016216506A (ja) 2009-04-28 2016-09-21 トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療

Country Status (15)

Country Link
US (3) US20100273894A1 (cg-RX-API-DMAC7.html)
EP (2) EP2424495B1 (cg-RX-API-DMAC7.html)
JP (3) JP2012525399A (cg-RX-API-DMAC7.html)
BR (1) BRPI1013376A8 (cg-RX-API-DMAC7.html)
CA (1) CA2777479C (cg-RX-API-DMAC7.html)
DK (1) DK2424495T3 (cg-RX-API-DMAC7.html)
EA (1) EA031126B1 (cg-RX-API-DMAC7.html)
ES (1) ES2662051T3 (cg-RX-API-DMAC7.html)
HU (1) HUE037574T2 (cg-RX-API-DMAC7.html)
MX (1) MX336800B (cg-RX-API-DMAC7.html)
NO (1) NO2424495T3 (cg-RX-API-DMAC7.html)
PL (1) PL2424495T3 (cg-RX-API-DMAC7.html)
PT (1) PT2424495T (cg-RX-API-DMAC7.html)
SI (1) SI2424495T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010126911A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021121594A (ja) * 2015-06-05 2021-08-26 フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ ミトコンドリア病の治療

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033093A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
DK2471530T3 (en) * 2005-06-01 2017-04-10 Edison Pharmaceuticals Inc REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
HUE028502T2 (en) 2007-11-06 2016-12-28 Edison Pharmaceuticals Inc 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases
EP2237664A4 (en) * 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
US8716527B2 (en) 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
LT3827815T (lt) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
US20110207828A1 (en) * 2009-08-26 2011-08-25 Miller Guy M Methods for the prevention and treatment of cerebral ischemia
CA2797644A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2012069221A1 (en) * 2010-11-22 2012-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutical method for the treatment of the leber optic
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006737A1 (en) * 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc. Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
US9730949B2 (en) 2012-06-29 2017-08-15 Raouf Rekik Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy
US9629815B2 (en) 2012-09-07 2017-04-25 Bioelectron Technology Corporation Benzoquinone derivatives for treating oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
CA2906145A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US20160317606A1 (en) * 2014-01-06 2016-11-03 Stealth Bio Therapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
NZ733528A (en) 2014-12-16 2021-07-30 Ptc Therapeutics Inc Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CA3113290A1 (en) * 2018-10-11 2020-04-16 Imbria Pharmaceuticals, Inc. Compositions and methods for treating and preventing leber's hereditary optic neuropathy
RU2704013C1 (ru) * 2019-04-18 2019-10-23 ФГБНУ "НИИ глазных болезней" Способ коррекции окислительного стресса при наследственной оптической нейропатии Лебера
CN112385783B (zh) 2020-10-10 2022-07-05 南京农业大学 一种控制炭烤肉中多环芳烃含量的烤制方法
WO2024259130A1 (en) * 2023-06-16 2024-12-19 Ptc Therapeutics, Inc. Methods for increasing vatiquinone plasma exposure with food

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542389A (ja) * 2005-06-01 2008-11-27 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の状態の治療、およびエネルギーバイオマーカーの調節のための酸化還元活性治療薬
JP2009527567A (ja) * 2006-02-22 2009-07-30 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4875564A (cg-RX-API-DMAC7.html) 1972-01-08 1973-10-11
JPS4988862A (cg-RX-API-DMAC7.html) 1972-12-29 1974-08-24
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
JPH029875A (ja) 1988-03-16 1990-01-12 Bio Ind Kyokai トコフェロール及びトコトリエノールの製造方法
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
EP0543417A1 (en) 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
US5318993A (en) * 1993-04-16 1994-06-07 Bristol-Myers Squibb Company Antihyperlipidemic benzoquinones
WO1995030420A1 (en) 1994-05-06 1995-11-16 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
CN1167418C (zh) 1994-12-28 2004-09-22 詹森药业有限公司 奈必洛尔作为抗动脉粥样化剂的用途
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
JP2002501915A (ja) 1998-01-29 2002-01-22 イーストマン ケミカル カンパニー トコール含有混合物からのトコールの分離方法
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
DE10034233A1 (de) 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
GB0023555D0 (en) * 2000-09-26 2000-11-08 Inst Of Ophthalmology Improvements in and relating to treatments for eye disease
WO2002047680A2 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
US7119117B2 (en) 2001-08-21 2006-10-10 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
EP1450787A4 (en) 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc FORMULATIONS AND METHODS FOR THE TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
EP1378753B1 (en) 2002-07-01 2006-05-31 Santhera Pharmaceuticals (Schweiz) GmbH A screening method and compounds for treating Friedreich Ataxia
CA2504334A1 (en) 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
US7015243B2 (en) * 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
WO2005033093A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
US20050074447A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Treatment for diabetic microvascular and macrovascular complications
WO2005035491A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
US8182990B2 (en) 2004-03-18 2012-05-22 Rusk Intellectual Reserve Ag Method for diagnosing or predicting susceptibility to optic neuropathy
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006116262A1 (en) 2005-04-22 2006-11-02 Barrie Tan Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
ES2823728T3 (es) 2005-09-15 2021-05-10 Ptc Therapeutics Inc Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía
EP1924292A2 (en) 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US20100056429A1 (en) 2007-01-10 2010-03-04 Miller Guy M Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2009003694A2 (en) * 2007-07-03 2009-01-08 Andreas Reichert Method for treating diseases related to mitochondrial dysfunction
JP2010536797A (ja) 2007-08-16 2010-12-02 マクサイト， インコーポレイテッド 眼の疾患または状態を治療するための製剤
US8075909B2 (en) 2007-09-04 2011-12-13 University Of Florida Research Foundation, Incorporated Contact lens based bioactive agent delivery system
HUE028502T2 (en) 2007-11-06 2016-12-28 Edison Pharmaceuticals Inc 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases
CA2710253A1 (en) 2008-01-07 2009-07-16 Centocor Ortho Biotech Inc. Method of treating erythropoietin hyporesponsive anemias
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
US20110046156A1 (en) 2008-03-05 2011-02-24 Miller Guy M Treatment of hearing and balance impairments with redox-active therapeutics
US8716527B2 (en) 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
CA2723621A1 (en) 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
EP2303309A2 (en) 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
WO2010014361A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
LT3827815T (lt) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
CA2739658C (en) 2008-10-09 2016-11-08 Ramscor, Inc. Composition and method for treating dry eye syndrome
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
EA201101576A1 (ru) 2009-04-28 2012-04-30 Эдисон Фармасьютикалз, Инк. Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
BRPI1015006A2 (pt) 2009-04-28 2019-09-24 Ampere Life Sciences Inc uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas
US20120122969A1 (en) 2009-06-25 2012-05-17 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
US20110207828A1 (en) 2009-08-26 2011-08-25 Miller Guy M Methods for the prevention and treatment of cerebral ischemia
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
CA2797644A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
JP2013523816A (ja) 2010-04-06 2013-06-17 エジソン ファーマシューティカルズ， インコーポレイテッド 毛細血管拡張性運動失調症の治療
MY183449A (en) 2010-04-27 2021-02-18 Bioelectron Tech Corp Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
JP2013538799A (ja) 2010-08-06 2013-10-17 アンペア ライフ サイエンシーズ，インコーポレイテッド ビタミンｋを用いたミトコンドリア病の処置
CA2807507A1 (en) 2010-08-06 2012-02-09 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with naphthoquinones
US20120295985A1 (en) 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006737A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc. Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
US9629815B2 (en) 2012-09-07 2017-04-25 Bioelectron Technology Corporation Benzoquinone derivatives for treating oxidative stress disorders
CN105142603B (zh) 2013-03-08 2018-10-19 荷兰联合利华有限公司 用于皮肤病用途的间苯二酚化合物
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
CA2906145A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
AU2014273891A1 (en) 2013-05-31 2015-12-24 Bioelectron Technology Corporation Carboxylic acid derivatives for treatment of oxidative stress disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542389A (ja) * 2005-06-01 2008-11-27 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の状態の治療、およびエネルギーバイオマーカーの調節のための酸化還元活性治療薬
JP2009527567A (ja) * 2006-02-22 2009-07-30 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A OLICHON ET AL.: "Effects of OPA1 Mutations on Mitochondrial Morphology and Apoptosis: Relevance to ADOA Pathogenesis", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 211, JPN6015009585, 19 October 2006 (2006-10-19), pages 423 - 430, ISSN: 0003026436 *
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1763, JPN6014020274, 2006, pages 500 - 509, ISSN: 0002814278 *
C DELETTRE ET AL.: "OPA1(Kjer Type) Dominant Optic Atrohy: A Novel Mitochondrial Disease", MOLECULAR GENETICS AND METABOLISM, vol. 75, JPN6015009592, 28 November 2001 (2001-11-28), pages 97 - 107, ISSN: 0003026438 *
HUDSON G: "LEBER HEREDITARY OPTIC NEUROPATHY", EXPERT OPINION ON MEDICAL DIAGNOSTICS, vol. V2 N7, JPN5012012682, 1 July 2008 (2008-07-01), GB, pages 789 - 799, ISSN: 0002814277 *
M MILONE ET AL.: "Mitochondrial disorder wiht OPA1 mutation lacking optic atrophy", MITOCHONDRION, vol. 9, JPN6015009588, 20 March 2009 (2009-03-20), pages 279 - 281, ISSN: 0003026437 *
神野 早苗: "遺伝性視神経症の乳頭所見", あたらしい眼科, vol. 23, no. 5, JPN6015009582, 2006, pages 587 - 591, ISSN: 0003026435 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021121594A (ja) * 2015-06-05 2021-08-26 フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ ミトコンドリア病の治療
JP2023123444A (ja) * 2015-06-05 2023-09-05 フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ ミトコンドリア病の治療
US11998551B2 (en) 2015-06-05 2024-06-04 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Treatment of mitochondrial diseases

Also Published As

Publication number Publication date
EP2424495A1 (en) 2012-03-07
US10195161B2 (en) 2019-02-05
EP2424495B1 (en) 2018-01-17
CA2777479A1 (en) 2010-11-04
EA031126B1 (ru) 2018-11-30
CA2777479C (en) 2017-10-17
US20140039065A1 (en) 2014-02-06
US20170119695A1 (en) 2017-05-04
BRPI1013376A2 (pt) 2017-03-21
US9370496B2 (en) 2016-06-21
ES2662051T3 (es) 2018-04-05
EA201101575A1 (ru) 2012-04-30
WO2010126911A1 (en) 2010-11-04
US20100273894A1 (en) 2010-10-28
PT2424495T (pt) 2018-03-13
EP3332766A1 (en) 2018-06-13
NO2424495T3 (cg-RX-API-DMAC7.html) 2018-06-16
BRPI1013376A8 (pt) 2018-01-09
MX336800B (es) 2016-02-02
JP2016216506A (ja) 2016-12-22
PL2424495T3 (pl) 2018-06-29
JP2015028084A (ja) 2015-02-12
SI2424495T1 (en) 2018-04-30
DK2424495T3 (en) 2018-04-30
HUE037574T2 (hu) 2018-09-28
MX2011011309A (es) 2011-11-18

Similar Documents

Publication Publication Date Title
US10195161B2 (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
AU2011245384B9 (en) Formulations of quinones for the treatment of ophthalmic diseases
AU2011245384B2 (en) Formulations of quinones for the treatment of ophthalmic diseases
US20100273892A1 (en) Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
EP2585057B1 (en) Methods of treatment using sterculic acid
HK1168028B (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
HK1168028A (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
ES2252808T3 (es) Utilizacion de tiaminas para fabricar un medicamento destinado a la prevencion y al tratamiento de retinopatias y nefropatias al diabetico.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150311

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150713